查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
軟骨發育不全治療市場：按治療類型、給藥途徑、分銷管道和地區 - 2023 年至 2030 年的市場規模、份額、前景和機會分析
市場調查報告書
商品編碼
1349788

軟骨發育不全治療市場：按治療類型、給藥途徑、分銷管道和地區 - 2023 年至 2030 年的市場規模、份額、前景和機會分析

Achondroplasia Treatment Market, by Treatment Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 207 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

到 2023 年，全球軟骨發育不全治療市場估計為 1.278 億美元，預計在預測期內（2023-2030 年）複合年增長率為 36.5%。

報告範圍 報告詳細資料
基準年 2022 2023 年市場規模 美國：1.278億美元
過去的資料 2018年至2021年 預測期間 2023-2030
預測 2023-2030 年複合年增長率： 36.50% 2030年價值預測 美國：11.26億美元
軟骨發育不全治療市場-IMG1

軟骨發育不全是一種四肢短小的侏儒症。 軟骨發育不全的特徵是軀幹大小中等、手臂和腿部較短，尤其是上臂和大腿較短、肘部活動範圍有限以及頭部增大。 椎管狹窄是椎管狹窄，壓迫脊髓上部，可能是軟骨發育不全的嚴重併發症。 椎管狹窄的特徵是腿部疼痛、麻木和無力，導致行走困難。 軟骨發育不全是 FGFR3 基因突變引起的。 FGFR3 基因負責提供製造參與骨骼和腦組織發育和維護的蛋白質的指令。

市場動態

監管機構對軟骨發育不全治療的核准增加預計將在預測期內推動市場成長。 例如，2021年11月，全球生物技術公司BioMarin宣布，美國食品藥物管理局（FDA）已確認，美國食品藥物管理局（FDA）已確認線性化藥物已獲得加速批准。注射用VOXZOGO（vosoritide ）以指示生長加快。 此外，2021年8月，BridgeBio Pharma旗下QED Therapeutics宣布，歐盟委員會（EC）宣布生長板從2歲到青春期接近並達到最終高度，我們宣布已獲得上市批准VOXZOGO（通用名：vosoritide），每日一次注射劑，用於治療軟骨發育不全。

此外，主要公司加大對軟骨發育不全治療的研究和開發預計將在預測期內推動治療領域的成長。 例如，專門從事適體療法的臨床階段製藥公司 RIBOMIC, Inc. 於 2021 年 11 月宣布開展 RBM-007 的 1 期臨床試驗，用於計劃治療健康患者的軟骨發育不全。我們公佈了志願者臨床結果審判於2021 年5 月結束。

本次考試的主要特色

  • 本報告詳細分析了全球軟骨發育不全治療市場，並介紹了以 2022 年為基準年的預測期（2023-2030 年）的市場規模和復合年增長率。
  • 它也揭示了各個細分市場的潛在收入機會，並為該市場提供了一系列有吸引力的投資建議。
  • 它還提供了有關市場驅動因素、限制因素、機會、新產品發布和批准、市場趨勢、區域前景、主要參與者採取的競爭策略等的重要見解。
  • 根據公司亮點、產品組合、主要亮點、績效和策略等參數對全球軟骨發育不全治療市場的主要參與者進行了分析。
  • 本研究涵蓋的主要公司包括 BioMarin, RIBOMIC, Ascendis Pharma A/S, BridgeBio Pharma, Inc., Pfizer Inc., PhaseBio Pharmaceuticals, Inc., SiSaf, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, LG Chem, Ferring B.V., JCR Pharmaceuticals Co., Ltd, KVK TECH, INC., VIVUS LLC., ProLynx Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Ipsen Pharma, Novartis AG, and Xiamen Amoytop Biotech Co., Ltd.。
  • 本研究報告分析了全球軟骨發育不全治療市場，包括產品類型、性能、財務狀況和策略等資訊。
  • 《全球軟骨發育不全治療市場報告》面向該產業的各個利害關係人，例如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 利害關係人可以透過用於分析全球軟骨發育不全治療市場的各種策略矩陣來促進決策。

目錄

第一章研究目的與前提

  • 研究目的
  • 先決條件
  • 縮寫

第二章市場概述

  • 報告摘要
    • 市場定義和範圍
  • 執行摘要

第三章市場動態、法規與趨勢分析

  • 市場動態
    • 促進因素
    • 抑制因素
    • 市場機會
  • 影響分析
  • 近期新藥發布
  • 流行病學
  • 合併、收購、聯盟
  • 監管場景
  • 主要進展
  • PEST分析

第 4 章全球軟骨發育不全治療市場：COVID-19 的影響分析

  • 經濟影響
  • COVID-19 的流行病學
  • 對需求和供給的影響

第 5 章軟骨發育不全治療的全球市場：依治療類型劃分，2018-2030 年

  • 沃索裡□
  • 人類生長激素
  • 其他

第 6 章軟骨發育不全治療的全球市場：依給藥途徑劃分，2018-2030 年

  • 口頭
  • 注射用

第 7 章軟骨發育不全治療的全球市場：依通路劃分，2018-2030 年

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 8 章軟骨發育不全治療的全球市場：按地區劃分，2018-2030 年

  • 北美
  • 美國
  • 加拿大
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 歐洲其他地區
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 東協
  • 澳大利亞
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲地區
  • 中東
  • 海灣合作委員會
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中非
  • 南非

第九章競爭態勢

  • 公司簡介
    • BioMarin
    • RIBOMIC
    • Ascendis Pharma A/S
    • BridgeBio Pharma, Inc.
    • Pfizer Inc.
    • PhaseBio Pharmaceuticals, Inc.
    • SiSaf
    • Novo Nordisk A/S
    • F.Hoffmann-La Roche Ltd
    • LG Chem
    • Ferring B.V.
    • JCR Pharmaceuticals Co., Ltd
    • KVK TECH, INC.
    • VIVUS LLC.
    • ProLynx Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Ipsen Pharma
    • Novartis AG
    • Xiamen Amoytop Biotech Co., Ltd.

第 10 章

  • 參考文獻
  • 調查方法
簡介目錄
Product Code: CMI4161

The global achondroplasia treatment market is estimated to be valued at US$ 127.8 million in 2023 and is expected to exhibit a CAGR of 36.5% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 127.8 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 36.50% 2030 Value Projection: US$ 1,126.0 Mn
Achondroplasia Treatment Market - IMG1

Achondroplasia is a form of short-limbed dwarfism. Achondroplasia is characterized by an average-sized trunk, short arms and legs, notably short upper arms and thighs, a limited range of motion at the elbows, and an enlarged head. Spinal stenosis, a narrowing of the spinal canal that can compress the upper section of the spinal cord, is a potentially serious complication of achondroplasia. Spinal stenosis is characterized by leg pain, tingling, and weakness, which can make walking difficult. Achondroplasia is caused by mutations in the FGFR3 gene. The FGFR3 gene is responsible for giving instructions when making a protein that is involved in the development and maintenance of bone and brain tissue.

Market Dynamics

Increasing approvals of achondroplasia treatment drugs by regulatory bodies are expected to drive the market growth over the forecast period. For instance, in November 2021, BioMarin, a global biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval to VOXZOGO (vosoritide) for injection, indicated to increase linear growth in pediatric patients with achondroplasia of five years of age and older with open epiphyses (growth plates). Moreover, in August 2021, QED Therapeutics, a subsidiary of BridgeBio Pharma, Inc., announced that the European Commission (EC) had granted marketing authorization for VOXZOGO (vosoritide), a once-daily injection to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height.

Also, increasing research and development by key players for the treatment of achondroplasia is expected to drive the treatment segment growth over the forecast period. For instance, in November 2021, RIBOMIC, Inc., a clinical stage pharmaceutical company specialized in aptamer therapeutics, announced the results from its Phase 1, healthy volunteer clinical study using RBM-007 for the planned treatment of achondroplasia, which was completed in May 2021.

Key features of the study:

  • This report provides an in-depth analysis of the global achondroplasia treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global Achondroplasia Treatment market based on the following parameters- Company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include BioMarin, RIBOMIC, Ascendis Pharma A/S, BridgeBio Pharma, Inc., Pfizer Inc., PhaseBio Pharmaceuticals, Inc., SiSaf, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, LG Chem, Ferring B.V., JCR Pharmaceuticals Co., Ltd, KVK TECH, INC., VIVUS LLC., ProLynx Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Ipsen Pharma, Novartis AG, and Xiamen Amoytop Biotech Co., Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global achondroplasia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global achondroplasia treatment market.

Detailed Segmentation:

  • Global Achondroplasia Treatment Market, By Treatment Type:
    • Vosoritide
    • Human Growth Hormone
    • Others
  • Global Achondroplasia Treatment Market, By Route of Administration:
    • Oral
    • Parenteral
  • Global Achondroplasia Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Achondroplasia Treatment, By Region:
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • BioMarin
    • RIBOMIC
    • Ascendis Pharma A/S
    • BridgeBio Pharma, Inc.
    • Pfizer Inc.
    • PhaseBio Pharmaceuticals, Inc.
    • SiSaf
    • Novo Nordisk A/S
    • F.Hoffmann-La Roche Ltd
    • LG Chem
    • Ferring B.V.
    • JCR Pharmaceuticals Co., Ltd
    • KVK TECH, INC.
    • VIVUS LLC.
    • ProLynx Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly and Company
    • Ipsen Pharma
    • Novartis AG
    • Xiamen Amoytop Biotech Co., Ltd.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Treatment Type
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Drug Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global Achondroplasia Treatment Market, COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Achondroplasia Treatment Market, By Treatment Type, 2018 - 2030 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Vosoritide
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Human Growth Hormone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

6. Global Achondroplasia Treatment Market, By Route of Administration, 2018 - 2030 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

7. Global Achondroplasia Treatment Market, By Distribution Channel, 2018 - 2030 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

8. Global Achondroplasia Treatment Market, By Regions, 2018 - 2030 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profiles
    • BioMarin
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • RIBOMIC
    • Ascendis Pharma A/S
    • BridgeBio Pharma, Inc.
    • Pfizer Inc.
    • PhaseBio Pharmaceuticals, Inc.
    • SiSaf
    • Novo Nordisk A/S
    • F.Hoffmann-La Roche Ltd
    • LG Chem
    • Ferring B.V.
    • JCR Pharmaceuticals Co., Ltd
    • KVK TECH, INC.
    • VIVUS LLC.
    • ProLynx Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Ipsen Pharma
    • Novartis AG
    • Xiamen Amoytop Biotech Co., Ltd.

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact